Pharmacogenomics : social, ethical, and clinical dimensions /
"Pharmacogenomics promises to revolutionize medicine by enabling the prevention, diagnosis, and treatment of diseases at the genome level. While a substantial amount of public and private research focuses on new pharmacogenomic applications, notably less attention has been directed to the ethic...
Պահպանված է:
| Այլ հեղինակներ: | |
|---|---|
| Ձևաչափ: | Գիրք |
| Լեզու: | English |
| Հրապարակվել է: |
Hoboken, N.J. :
Wiley-Liss,
c2003.
|
| Խորագրեր: | |
| Առցանց հասանելիություն: | Publisher description Book review (E-STREAMS) Table of contents |
| LEADER | 03900cam a2200493 a 4500 | ||
|---|---|---|---|
| 001 | c000404456 | ||
| 003 | CARM | ||
| 005 | 20190429105904.0 | ||
| 008 | 190429s2003 njua b 001 0 eng | ||
| 010 | |a 2002012137 | ||
| 015 | |a GBA4-14658 | ||
| 016 | |a 000023809033 |2 AU | ||
| 019 | 1 | |a 23809033 |5 LACONCORD2021 | |
| 020 | |a 0471227692 (cloth) | ||
| 024 | 8 | |a 99806191057 | |
| 035 | |a (OCoLC)50285701 |5 LACONCORD2021 | ||
| 040 | |a DNLM/DLC |b eng |c DLC |d DLC |d DNLM/DLC |d NUN | ||
| 042 | |a pcc | ||
| 050 | 0 | 0 | |a RM301.3.G45 |b P435 2003 |
| 060 | 1 | 0 | |a QV 38 |b P53197 2003 |
| 082 | 0 | 0 | |a 615/.7 |2 21 |
| 245 | 0 | 0 | |a Pharmacogenomics : |b social, ethical, and clinical dimensions / |c edited by Mark A. Rothstein. |
| 260 | |a Hoboken, N.J. : |b Wiley-Liss, |c c2003. | ||
| 300 | |a xii, 368 p. : |b ill. ; |c 24 cm. | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Public attitudes about pharmacogenomics / Mark A. Rothstein and Carlton A. Hornung -- Pharmacogenomics: pharmacology and toxicology in the genomics era / Harvey W. Mohrenweiser -- The implications of population genetics for pharmacogenomics / Craig L. Hanis -- Genome research and minorities / Henry T. Greely -- Drug development strategies / Penelope K. Manasco and Teresa E. Arledge -- Drug development, regulation, and genetically guided therapy / David W. Feigal and Steven I. Gutman -- Intellectual property and commercial aspects of pharmacogenomics / Allen C. Nunnally, Scott A. Brown, and Gary A. Cohen -- Integration of pharmacogenomics into medical practice / Gilbert S. Omenn and Arno G. Motulsky -- Clinical utility of pharmacogenetics and pharmacogenomics / Neil A. Holtzman -- Medical liability for pharmacogenomics -- Larry I. Palmer -- The challenges of pharmacogenomics for pharmacy education / David B. Brushwood -- Economic implications of pharmacogenomics / C.E. Reeder and W. Michael Dickson -- Pharmacogenomics and the social construction of identity / Morris W. Foster -- Pharmacogenomics: considerations for communities of color / Laurie Nsiah-Jefferson -- Constitutional issues in the use of pharmacogenomic variations associated with race / John A. Robertson. | |
| 520 | 1 | |a "Pharmacogenomics promises to revolutionize medicine by enabling the prevention, diagnosis, and treatment of diseases at the genome level. While a substantial amount of public and private research focuses on new pharmacogenomic applications, notably less attention has been directed to the ethical, legal, and social implications of "individualized medicine. "Mark Rothstein's timely anthology reduced that scholarship deficit, presenting a multidisciplinary analysis of the scientific, clinical economic, ethical, social, and legal implications of pharmacogenomics." "Biotechnology and pharmaceutical researchers and regulators, health care professionals and students, and academics and policymakers will find Pharmacogenomic to be a valuable resource."--BOOK JACKET. | |
| 650 | 2 | 2 | |a Drug Design. |
| 650 | 2 | 2 | |a Ethics, Medical. |
| 650 | 2 | 2 | |a Legislation, Medical. |
| 650 | 2 | 2 | |a Public Policy. |
| 650 | 2 | 2 | |a Social Environment. |
| 650 | 1 | 2 | |a Pharmacogenetics. |
| 650 | 0 | |a Pharmacogenomics. | |
| 700 | 1 | |a Rothstein, Mark A. | |
| 852 | 8 | |b CARM |i B12771 |p 0655015 |f BK | |
| 852 | 8 | |b SCAN |h A3:AP01B0 |i B12771 |p 0655015 |f BK | |
| 852 | 8 | |b SCAN |h A3:AP01B0 |i B12771 |p 0655015 |f BK | |
| 856 | 4 | 2 | |3 Publisher description |u http://www.loc.gov/catdir/description/wiley039/2002012137.html |
| 856 | 4 | 2 | |3 Book review (E-STREAMS) |u http://www.e-streams.com/es0607/es0607_2605.html |
| 856 | 4 | 1 | |3 Table of contents |u http://www.loc.gov/catdir/toc/wiley031/2002012137.html |
| 999 | f | f | |i ba71cd12-5d35-509e-a8c5-bc111aefe76d |s 873592df-2044-55cd-b0c0-bb5d5b19b5d3 |
| 952 | f | f | |p Can circulate |a CAVAL |b CAVAL |c CAVAL |d CARM 1 Store |e B12771 |h Other scheme |i book |m 0655015 |
| 952 | f | f | |a CAVAL |b CAVAL |c CAVAL |d Unmapped Location |e B12771 |f A3:AP01B0 |h Other scheme |